论文部分内容阅读
目的 :探讨CD4 4分子与非何杰金淋巴瘤恶性程度和临床分期的关系。方法 :应用骨髓单个核细胞进行免疫组化 (SABC)的方法 ,检测非何杰金淋巴瘤骨髓CD4 4阳性率。结果 :非何杰金淋巴瘤骨髓CD4 4阳性率为 80 % ,实验组与对照组阳性率有显著性差异 (P <0 .0 1) ,实验组单个核细胞CD4 4阳性率随病程分期增加阳性率逐渐增高 (P <0 .0 1) ,随恶性程度增加阳性率增加 (P <0 .0 5 )。结论 :非何杰金淋巴瘤病人骨髓单个核细胞CD4 4表达增高 ,且CD4 4的增高与临床病程和恶性程度有关。预测非何杰金淋巴瘤患者的病程和恶性程度。
Objective: To investigate the relationship between CD4 4 molecule and malignancy and clinical stage of non-Hodgkin’s lymphoma. Methods: Immunohistochemistry (SABC) was performed on bone marrow mononuclear cells to detect the CD4 4 positive rate in non-Hodgkin’s lymphoma. Results: The positive rate of CD4 4 in bone marrow of non-Hodgkin’s lymphoma was 80%. There was significant difference between the experimental group and the control group (P <0.01). The positive rate of CD4 4 in mononuclear cells of experimental group increased with the stage of disease The positive rate increased gradually (P <0.01), and the positive rate increased with the increase of malignant degree (P <0.05). Conclusion: The expression of CD4 4 in bone marrow mononuclear cells of patients with non-Hodgkin’s lymphoma is increased, and the increase of CD4 4 is correlated with the clinical course and degree of malignancy. Predict the course and severity of non-Hodgkin’s lymphoma.